Boston Scientific Corporation vs Invesco NASDAQ 100 ETF — how do they compare? Boston Scientific Corporation trades at $51.28 (market cap $74.19B), while Invesco NASDAQ 100 ETF trades at $297.78. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | QQQM | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $307.23 |
52-Week Low | $42.63 | $229.87 |
Enterprise Value | $86.27B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
QQQM, tracking the Nasdaq-100, trades at $298.55, up 0.59% with a bullish technical signal from moving averages. The ETF benefits from lower fees compared to QQQ, attracting cost-conscious investors. Recent news highlights its inclusion in retirement portfolios and strong inflows into Nasdaq-focused ETFs, supported by tech sector performance.
Outlook remains positive due to tech-led growth, but risks include market volatility and concentration in mega-cap stocks. The ETF offers exposure to high-growth companies, with institutional activity showing mixed signals, such as Bank of America reducing its position in Q2 2026.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →